Aligos’ 2034‑35 Stock‑Option Grants Signal Management Commitment Amid Biotech Valuation Pressure
Aligos’ new long‑dated stock options signal management’s confidence in upcoming clinical milestones, yet investors should monitor FDA approvals, partnership moves, and market volatility to assess potential upside versus risk.
4 minutes to read